Clinical results of definitive intensity-modulated radiation therapy for oropharyngeal cancer: retrospective analysis of treatment efficacy and safety.

Abstract

OBJECTIVE:

To evaluate the clinical outcomes of intensity-modulated radiotherapy for patients with oropharyngeal carcinoma.

METHODS:

Ninety-three oropharyngeal carcinoma patients histopathologically diagnosed with squamous cell carcinoma and treated with definitive intensity-modulated radiotherapy using helical tomotherapy between January 2006 and December 2013 were analyzed. Planning target volume primary and involved nodes was delivered 66-70 Gy at 2 Gy per fraction, while planning target volume prophylactic was delivered 54 Gy using the simultaneous integrated boost technique.

RESULTS:

The median follow-up period among the surviving patients was 40 months (range, 13-96). There were 76 males and 17 females with a median age of 60 years (range, 34-80). The disease was Stage II in 13%, Stage III in 10% and Stage IV in 77% of patients. Ninety-two patients received chemotherapy (99%); 68 patients received induction chemotherapy (73%), while 21 received concurrent chemotherapy (23%). The 3-year overall survival, progression-free survival and locoregional control rates were 80, 68 and 79%, respectively. Multivariate analysis identified an advanced T-category (T3-4), having double cancer, and smoking habit as significantly unfavorable factors for overall survival, progression-free survival and both progression-free survival and locoregional control, respectively. Only two patients who achieved disease control required percutaneous endoscopic gastrostomy tubes in the last follow-up. The rate of Grade 2 xerostomia at 2 years was 23%.

CONCLUSIONS:

Intensity-modulated radiotherapy using helical tomotherapy for patients with oropharyngeal carcinoma provided not only sufficient efficacy, but also preserved parotid function.

• Authors: Kana Kimura, Takeshi Kodaira, Natsuo Tomita, Hiroyuki Tachibana, Chiyoko Makita, Maiko Yoshida, Daisuke Nishikawa, Hitoshi Hirakawa, Hidenori Suzuki, Nobuhiro Hanai, Yasuhisa Hasegawa
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 46 Issue 1 Pg. 78-85 (Jan 2016) ISSN: 1465-3621 [Electronic] England
• PMID: 26496935 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected].

Topics

• Adult
• Aged
• Carcinoma, Squamous Cell (pathology, radiotherapy)
• Chemoradiotherapy
• Disease-Free Survival
• Female
• Humans
• Induction Chemotherapy
• Male
• Middle Aged
• Oropharyngeal Neoplasms (radiotherapy)
• Parotid Gland (radiation effects)
• Radiotherapy, Intensity-Modulated (adverse effects)
• Retrospective Studies
• Safety
• Treatment Outcome
• Xerostomia (etiology)